Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464373 | 0.81 | TSHR (0.32) | HTR1AHTR1DHTR2CHTR7HTR5A | |
| SCHEMBL1172152 | 0.81 | TAAR1 (0.39) | HTR5ATAAR1 | |
| SCHEMBL1171691 | 0.79 | BACE1 (0.41) | TAAR1 | |
| SCHEMBL1171998 | 0.78 | CYP19A1 (0.35) | — | |
| SCHEMBL4468713 | 0.77 | HTT (0.39) | HTR1AHTR1DHTR2CHTR7HTR5A | |
| SCHEMBL1171710 | 0.76 | HSP90AA1 (0.37) | HTR5A | |
| SCHEMBL1171670 | 0.73 | AGPAT2 (0.38) | — | |
| SCHEMBL4458379 | 0.72 | CYP3A4 (0.35) | HTR5A | |
| SCHEMBL1172013 | 0.69 | BACE1 (0.42) | — | |
| SCHEMBL1172224 | 0.69 | BACE1 (0.32) | HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| EP-1981856-A2 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | EPHB4, EPHB1, EPHB3 | HTR1A 1758/4885HTR1D 2030/4885HTR2C 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.